Early evaluation of targeted therapy effectiveness in non-small cell lung cancer by dynamic contrast-enhanced CT

[1] Jemal A(2008)Cancer statistics, 2008 CA Cancer J Clin 58 71-96

[2] Siegel R(2002)Comparison of four chemotherapy regimens for advanced non-small cell lung cancer N Engl J Med 346 92-98

[3] Ward E(2005)Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 1527-1537

[4] Hao Y(2007)Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib Br J Cancer 96 1191-1196

[5] Xu J(2010)Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer Oncologist 15 436-446

[6] Murray T(2009)Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer Radiology 252 263-272

[7] Schiller JH(2013)Non-small cell lung cancer after surgery and chemoradiotherapy: follow-up and response assessment Diagn Interv Radiol 19 447-456

[8] Harrington D(2011)Whole-tumor perfusion CT in patients with advanced lung adenocarcinoma treated with conventional and antiangiogenic chemotherapy: initial experience Radiology 259 574-582

[9] Belani CP(2003)Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy Mod Pathol 16 1102-1108

[10] Langer C(2009)From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors J Nucl Med 50 122S-150S

[1] Jemal A(2008)Cancer statistics, 2008 CA Cancer J Clin 58 71-96

[2] Siegel R(2002)Comparison of four chemotherapy regimens for advanced non-small cell lung cancer N Engl J Med 346 92-98

[3] Ward E(2005)Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 1527-1537

[4] Hao Y(2007)Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib Br J Cancer 96 1191-1196

[5] Xu J(2010)Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer Oncologist 15 436-446

[6] Murray T(2009)Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer Radiology 252 263-272

[7] Schiller JH(2013)Non-small cell lung cancer after surgery and chemoradiotherapy: follow-up and response assessment Diagn Interv Radiol 19 447-456

[8] Harrington D(2011)Whole-tumor perfusion CT in patients with advanced lung adenocarcinoma treated with conventional and antiangiogenic chemotherapy: initial experience Radiology 259 574-582

[9] Belani CP(2003)Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy Mod Pathol 16 1102-1108

[10] Langer C(2009)From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors J Nucl Med 50 122S-150S